Professor Michael Parker
B.Ed (Hons), MA, PhD
Director of the Wellcome Centre for Ethics and Humanities, and the Ethox Centre
- Professor of Bioethics
Michael Parker is Director of the Wellcome Centre for Ethics and Humanities and Director of the Ethox Centre at the University of Oxford.
The Wellcome Centre for Ethics and Humanities conducts research on the ethical challenges that are posed by advances in neuroscience, data science, genomics and global connectedness, and by their convergence. Through its activities, the Centre aims to lead debate on the ethical requirements for 21st Century scientific research and to develop an ethics that is capable of both improving health and health care, and promoting and sustaining public trust and confidence. The Centre is supported by a Wellcome Centre Grant (203132).
Ethox is a multidisciplinary bioethics research Centre that aims to improve ethical standards in healthcare practice and in medical research through education, research, and the provision of ethics support to health professionals and researchers. Ethox aims in all its activities to be close to practice and to engage with ethical issues faced by real world actors in real world settings. Its research focusses on four areas: global health ethics, population health ethics, research ethics, and clinical ethics.
Michael’s own research interests are in the ethics of collaborative global health research, the uses of data-science in population health, and the clinical uses of genomics.
Together with partners at the Wellcome Trust Major Overseas Programmes (MOPs) in Vietnam, Malawi, Thailand-Laos, Kenya, and South Africa, Michael co-ordinates the Global Health Bioethics Network, which is designed to encourage and promote ethical reflection, carry out ethics research, and build ethics capacity across the MOPs. The Network is supported by a Wellcome Strategic Award (096527). Michael also leads the ethics programme of the Malaria Genomic Epidemiology Network (MalariaGEN), which carries out genomic research into severe malaria in childhood at 24 sites in 21 countries.
Michael is the Chair of the Genomics England Ethics Advisory Committee and a non-executive director of Genomics England, which is charged with implementing the UK’s 100,000 Genomes Project. Since 2001, with Anneke Lucassen, Tara Clancy, and Angus Clarke he has coordinated the Genethics Club, a national ethics forum in the United Kingdom in which health professionals and genetics laboratory staff meet to discuss the ethical issues arising in their day-to-day practice and to share good practice. This work has been published as Parker, M. Ethical Problems and Genetics Practice (Cambridge University Press, 2012).
Ethical problems and genetics practice
Parker M., (2012)
Ethical data release in genome-wide association studies in developing countries.
Parker M. et al, (2009), PLoS medicine, 6
Managing misaligned paternity findings in research including sickle cell disease screening in Kenya: 'consulting communities' to inform policy.
Marsh V. et al, (2013), Social science & medicine (1982), 96, 192 - 199
Motivations and perceptions of community advisory boards in the ethics of medical research: the case of the Thai-Myanmar border.
Maung Lwin K. et al, (2014), BMC medical ethics, 15
Big data phenotyping in rare diseases: some ethical issues.
Hallowell N. et al, (2018), Genet Med
Views of rare disease participants in a UK whole-genome sequencing study towards secondary findings: a qualitative study.
Mackley MP. et al, (2018), European journal of human genetics : EJHG, 26, 652 - 659
If you come from a well-known organisation, I will trust you: Exploring and understanding the community's attitudes towards healthcare research in Cambodia.
Pol S. et al, (2018), PloS one, 13
Opening Pandora's box?: ethical issues in prenatal whole genome and exome sequencing.
Horn R. and Parker M., (2018), Prenatal diagnosis, 38, 20 - 25
How do clinical genetics consent forms address the familial approach to confidentiality and incidental findings? A mixed-methods study.
Dheensa S. et al, (2018), Familial cancer, 17, 155 - 166